



Drug-Drug Interactions (DDI) and Personalized Medicine in Oncology

Guest Editors:

Dr. Michela Roberto

Medical Oncology Unit A,
Umberto I University Hospital,
Sapienza University, 00100 Rome,
Italy

Prof. Dr. Andrea Botticelli

Department of Radiological,
Oncological and Pathological
Sciences, Medical Oncology Unit,
Umberto I Hospital, Sapienza
University, 00161 Rome, Italy

Deadline for manuscript
submissions:

closed (25 June 2024)

Message from the Guest Editors

Drug–drug interactions (DDIs) are one of the main aspects within the personalized medicine field that concern the treatment of cancer patients, especially when multiple oral or non-oral drugs are being used. However, the clinical relevance of these interactions is not always investigated. DDIs can be pharmaceutical, pharmacokinetic, or pharmacodynamic. They can also be wanted (e.g., the use of ciclosporin to enhance the oral bioavailability of paclitaxel); unwanted (e.g., a combination of the antiviral agent sorivudine and oral fluorouracil analogues can lead to fatal complications); between cytotoxic drugs, cytotoxic drugs, and non-cytotoxic drugs; or with pharmaceutical vehicles. More attention should be paid to the recognition of potential drug interactions to especially identify any effect in terms of toxicity as well as activity in oncological and non-oncological drugs. Therefore, we search for articles (reviews or original papers) about DDIs in cancer patients, regardless of the type of tumor, to provide more information about this less-explored field.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com